SCHEMBL6703582

SCHEMBL6703582

C/C(=C/C(=O)O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR4A1 P22736 1/20 0.66
NR4A2 P43354 1/20 0.66
NR4A3 Q92570 1/20 0.66
CES2 O00748 2/20 0.59
SRD5A2 P31213 1/20 0.54
ALDH1A1 P00352 2/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
MAOB P27338 1/20 0.52
NPSR1 Q6W5P4 1/20 0.51
LMNA P02545 1/20 0.51
S1PR1 P21453 1/20 0.50
POLB P06746 1/20 0.49
KCNK3 O14649 1/20 0.49
P2RX1 P51575 1/20 0.48
GAA P10253 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6703585 1.00 NR4A1 (0.66) NR4A1NR4A2NR4A3CES2SRD5A2
SCHEMBL7961951 0.86 CES2 (0.57) NR4A1NR4A2NR4A3CES2SRD5A2
SCHEMBL7961946 0.86 CES2 (0.57) NR4A1NR4A2NR4A3CES2SRD5A2
SCHEMBL7961170 0.83 NPSR1 (0.55) CES2SRD5A2ALDH1A1MEN1KMT2A
SCHEMBL7961166 0.83 NPSR1 (0.55) CES2SRD5A2ALDH1A1MEN1KMT2A
SCHEMBL8956626 0.82 CES2 (0.61) CES2SRD5A2ALDH1A1MEN1KMT2A
SCHEMBL8956617 0.82 CES2 (0.61) CES2SRD5A2ALDH1A1MEN1KMT2A
SCHEMBL19592309 0.81 CES2 (0.58) CES2SRD5A2ALDH1A1MEN1KMT2A
SCHEMBL20806278 0.80 CES2 (0.56) CES2SRD5A2ALDH1A1MEN1KMT2A
SCHEMBL4021645 0.80 NR4A1 (1.00) NR4A1NR4A2NR4A3CES2SRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040006081-A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity ASTRAZENECA AB (SE) 2004-01-08 US disclosed
EP-1289957-A1 PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY AstraZeneca AB (SE) 2003-03-12 EP disclosed
WO-2001087839-A1 PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2001-11-22 WO disclosed
US-6281209-B1 Fungicidal alkoximinomethyldioxazine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2001-08-28 US disclosed
EP-0973728-A1 ACRYLIC ACID PHENYLESTER DERIVATIVES BAYER AG (DE) 2000-01-26 EP disclosed
EP-0970061-A1 FUNGICIDAL ALKOXIMINOMETHYLDIOXAZINE DERIVATIVES BAYER AG (DE) 2000-01-12 EP disclosed
WO-1998040365-A1 FUNGICIDAL ALKOXIMINOMETHYLDIOXAZINE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 1998-09-17 WO disclosed
WO-1998040351-A1 ACRYLIC ACID PHENYLESTER DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 1998-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006081-A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity CCR5, CCR2, CCR1 NR4A1 578/4885NR4A2 699/4885NR4A3 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.